Difference between revisions of "Non-small cell lung cancer, BRAF-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|Years of study" to "|Years of enrollment") |
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") Tags: mobile edit mobile web edit |
||
Line 44: | Line 44: | ||
===References=== | ===References=== | ||
− | # '''BRF113928:''' Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext link to original article] [https:// | + | # '''BRF113928:''' Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/28919011 PubMed] |
=Advanced or metastatic disease, previously treated, BRAF inhibitor-naive= | =Advanced or metastatic disease, previously treated, BRAF inhibitor-naive= | ||
Line 78: | Line 78: | ||
===References=== | ===References=== | ||
− | # '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30146-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https:// | + | # '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30146-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27283860 PubMed] |
[[Category:Non-small cell lung cancer regimens]] | [[Category:Non-small cell lung cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Lung cancers]] | [[Category:Lung cancers]] |
Revision as of 02:09, 25 February 2020
Section editor | |
---|---|
Travis Osterman, DO, MS Vanderbilt University Nashville, TN ![]() |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Advanced or metastatic disease, first-line
Dabrafenib & Trametinib
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Planchard et al. 2017 (BRF113928-untreated) | 2014-2015 | Phase II (RT) |
Biomarker Eligibility Criteria
- Biomarker: BRAF V600E
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed
Advanced or metastatic disease, previously treated, BRAF inhibitor-naive
Dabrafenib & Trametinib
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Planchard et al. 2016 (BRF113928-treated) | 2013-2015 | Phase II (RT) |
All enrolled patients had progressed on 1 to 3 prior regimens.
Biomarker Eligibility Criteria
- Biomarker: BRAF V600E
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to original article link to PMC article PubMed